Covid-19 reinfection seems not to be a ‘regular event’, WHO said Tuesday, reports UN News.

Speaking to journalists in Geneva, WHO spokesperson Dr Margaret Harris addressed concerns that the development could herald a new alert.

“The important – other important – thing to note is the numbers are very, very small,” she said.

“So this is one documented case in over 23 million and we will probably see other documented cases,” Harris said noting that it was not a regular event.

Read Also: Hong Kong man ‘reinfected’ with coronavirus

Nonetheless, Dr Harris noted that the reinfection signaled on Monday was significant.

Virus mutations

According to the University of Hong Kong scientists who announced the development, the virus strains that infected the man more than four months apart were different.

“The important thing here is that this is clear documentation,” the WHO spokesperson said.

“So, we’ve had anecdotal reports every now and then from people who’ve tested negative, then tested positive. And it hasn’t been clear up until this case whether that was simply a problem of testing or whether people were getting infected a second time.”

Priorities for the UN health agency include understanding “what this means in terms of (people’s) immunity”, Dr Harris said.

Read Also: Can you contract coronavirus twice?

Vaccine initiative gathers pace

Meanwhile, WHO said that more than 170 countries are cooperating on a global initiative to produce fairly priced COVID-19 vaccines once they are licensed and approved.

The COVID-19 Vaccine Global Access Facility (COVAX) initiative involves countries and vaccine manufacturers; it is led by WHO, the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi, the Vaccine Alliance.

In a statement, WHO said that COVAX has the world’s “largest and most diverse COVID-19 vaccine portfolio” with nine candidate vaccines, nine more “under evaluation and conversations underway with other major producers”.

WHO described the project as only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.

But it insisted that in order to secure enough doses of vaccines to protect the most vulnerable populations - such as health workers and the elderly – funding was needed by August 31 deadline.

Read Also: COVID-19: What is the risk of reinfection?